Antiarrhythmic drugs.
Roy
D
D
D000200:Action Potentials / Q000187:drug effects; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000638:Amiodarone / Q000627:therapeutic use; D000813:Anilides / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use; D001949:Bretylium Compounds / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002462:Cell Membrane / Q000187:drug effects / Q000502:physiology; D004206:Disopyramide / Q000627:therapeutic use; D004594:Electrophysiology; D016700:Encainide; D005424:Flecainide; D006801:Humans; D008012:Lidocaine / Q000031:analogs & derivatives / Q000627:therapeutic use; D008801:Mexiletine / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D011342:Procainamide / Q000627:therapeutic use; D011802:Quinidine / Q000627:therapeutic use; D016677:Tocainide
D000319:Adrenergic beta-Antagonists; D000813:Anilides; D000889:Anti-Arrhythmia Agents; D001949:Bretylium Compounds; D002121:Calcium Channel Blockers; D010880:Piperidines; D008801:Mexiletine; D016677:Tocainide; D008012:Lidocaine; D004206:Disopyramide; D011802:Quinidine; D005424:Flecainide; D011342:Procainamide; D000638:Amiodarone; C045166:bretylium; D016700:Encainide